- Home
- TCRT vs ATNF Comparison
TCRT vs ATNF Comparison
Compare TCRT & ATNF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TCRT
- ATNF
- Stock Information
- Founded
- TCRT 1998
- ATNF 2016
- Country
- TCRT United States
- ATNF United States
- Employees
- TCRT N/A
- ATNF N/A
- Industry
- TCRT Biotechnology: Pharmaceutical Preparations
- ATNF Biotechnology: Pharmaceutical Preparations
- Sector
- TCRT Health Care
- ATNF Health Care
- Exchange
- TCRT Nasdaq
- ATNF Nasdaq
- Market Cap
- TCRT 3.8M
- ATNF 3.8M
- IPO Year
- TCRT N/A
- ATNF N/A
- Fundamental
- Price
- TCRT $3.03
- ATNF $1.05
- Analyst Decision
- TCRT
- ATNF
- Analyst Count
- TCRT 0
- ATNF 0
- Target Price
- TCRT N/A
- ATNF N/A
- AVG Volume (30 Days)
- TCRT 12.3K
- ATNF 43.3K
- Earning Date
- TCRT 05-15-2025
- ATNF 05-15-2025
- Dividend Yield
- TCRT N/A
- ATNF N/A
- EPS Growth
- TCRT N/A
- ATNF N/A
- EPS
- TCRT N/A
- ATNF N/A
- Revenue
- TCRT $11,000.00
- ATNF N/A
- Revenue This Year
- TCRT $5,680,500.00
- ATNF N/A
- Revenue Next Year
- TCRT N/A
- ATNF N/A
- P/E Ratio
- TCRT N/A
- ATNF N/A
- Revenue Growth
- TCRT 83.33
- ATNF N/A
- 52 Week Low
- TCRT $1.31
- ATNF $0.66
- 52 Week High
- TCRT $11.00
- ATNF $17.75
- Technical
- Relative Strength Index (RSI)
- TCRT 60.98
- ATNF 49.77
- Support Level
- TCRT $2.50
- ATNF $1.01
- Resistance Level
- TCRT $2.80
- ATNF $1.10
- Average True Range (ATR)
- TCRT 0.21
- ATNF 0.08
- MACD
- TCRT 0.01
- ATNF -0.01
- Stochastic Oscillator
- TCRT 98.31
- ATNF 35.29
About TCRT Alaunos Therapeutics Inc.
Alaunos Therapeutics Inc is a clinical-stage cellular immuno-oncology company dedicated to the treatment of solid tumors through adoptive TCR-T cell therapy. It strikes cancer at its core by engineering cell therapies that target Neoantigens arising from genomic mutations. It has a single reportable and operating segment related to biopharmaceutical research and development.
About ATNF 180 Life Sciences Corp.
180 Life Sciences Corp was formed as a clinical-stage biotechnology company, focused on the development of therapeutics for unmet medical needs in chronic pain, inflammation, and fibrosis by employing research, and, where appropriate, combination therapy. In addition, it has acquired certain source code and intellectual property relating to the back-end technology platform to operate an online blockchain casino, and moving forward, it plans to focus the majority of its operations on the creation of the online blockchain casino, while looking to monetize certain prior development-stage therapeutic product candidates for unmet medical needs. It has one reportable operating segment, iGaming.